Motexafin gadolinium
From Wikipedia, the free encyclopedia
 |
|
|
Motexafin gadolinium
|
|
| Systematic (IUPAC) name | |
| ? | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C52H72GdN5O14 |
| Mol. mass | 1148.403 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Motexafin gadolinium (proposed tradename Xcytrin) is an inhibitor of thioredoxin reductase and ribonucleotide reductase. It has been proposed as a possible chemotherapeutic agent in the treatment of brain cancer.[1]
[edit] History
On May 9, 2006, a New Drug Application was submitted to the United States Food and Drug Administration (FDA) by Pharmacyclics, Inc.[2]
On December 2007, the FDA issued a not approvable letter for motexafin gadolinium.[3]
[edit] References
- ^ Richards G, Mehta M (2007). "Motexafin gadolinium in the treatment of brain metastases". Expert opinion on pharmacotherapy 8 (3): 351–9. doi:. PMID 17266469.
- ^ Pharmacyclics, Inc. press release - Pharmacyclics to Submit New Drug Application for Xcytrin for Treatment of Lung Cancer Patients With Brain Metastases
- ^ Pharmacyclics, Inc. press release - Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases
 |
This biochemistry article is a stub. You can help Wikipedia by expanding it. |
